Fungal secondary metabolites: A promising source of antineoplastic drugs

Current Cancer Therapy Reviews

Volumn 6, Issue 3, 2010, Pages 222-228

  Ahmed, Hanaa Y ^a   El Shikh, Hussin H ^a   Ghoneimy, Eglal A ^b   Ragab, Ahmed M ^b   Saad, Ayman A ^c   Hashem, Ahmed M ^d   El Sayed, Rania M ^e   El Shikh, Mohey Eldin M ^e  

^a AL AZHAR UNIVERSITY   (Egypt)

^b Assiut Branch   (Egypt)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d CAIRO UNIVERSITY   (Egypt)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Antineoplastic; Cancer; Fungi; Immunotoxin; Metabolites; Trichoderma

Indexed keywords

4 (HEX 1 YEN 3 ENE),4(PENT 1,3 DIENE) AMINE; ANTINEOPLASTIC AGENT; DRUG METABOLITE; IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 8H9; MONOCLONAL ANTIBODY B3; MONOCLONAL ANTIBODY C242; MONOCLONAL ANTIBODY LL2; MONOCLONAL ANTIBODY OVB3; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4; UNCLASSIFIED DRUG;

ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; BREAST CANCER; BREAST CARCINOGENESIS; BREAST SARCOMA; COLON CANCER; DRUG STRUCTURE; ESOPHAGUS CANCER; FUNGAL METABOLISM; GANODERMA LUCIDUM; GLIOMA; GROWTH INHIBITION; HEAD AND NECK CARCINOMA; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; NONHUMAN; OPHIOCORDYCEPS; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PENICILLIUM; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; STOMACH CANCER; STREPTOMYCES; TRICHODERMA VIRIDE;

EID: 77958033656     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339410791698223     Document Type: Review

References (93)

1. Reedy JL, Bastidas RJ, Heitman J. The virulence of human pathogenic fungi: notes from the South of France. Cell Host Microbe 2007; 2: 77-83.
2. Madsen AM, Hansen VM, Meyling NV, Eilenberg J. Human exposure to airborne fungi from genera used as biocontrol agents in plant production. Ann Agric Environ Med 2007; 14: 5-24.
3. Casadevall A, Pirofski LA. The weapon potential of human pathogenic fungi. Med Mycol 2006; 44: 689-96.
4. Cooley JD, Wong WC, Jumper CA, Straus DC. Fungi and the indoor environment: their impact on human health. Adv Appl Microbiol 2004; 55: 1-30.
5. van Burik JA, Magee PT. Aspects of fungal pathogenesis in humans. Annu Rev Microbiol 2001; 55: 743-72.
6. Richard JL. Some major mycotoxins and their mycotoxicoses - an overview. Int J Food Microbiol 2007; 119: 3-10.
7. Bhatnagar D, Yu J, Ehrlich KC. Toxins of filamentous fungi. Chem Immunol 2002; 81: 167-206.
8. Bennett JW, Klich M. Mycotoxins. Clin Microbiol Rev 2003; 16: 497-516.
9. Wagacha JM, Muthomi JW. Mycotoxin problem in Africa: current status, implications to food safety and health and possible management strategies. Int J Food Microbiol 2008; 124: 1-12.
10. Hussein HS, Brasel JM. Toxicity, metabolism, and impact of mycotoxins on humans and animals. Toxicology 2001; 167: 101-34.
11. Schneider P, Misiek M, Hoffmeister D. In vivo and in vitro production options for fungal secondary metabolites. Mol Pharm 2008; 5: 234-42.
12. Misiek M, Hoffmeister D. Fungal genetics, genomics, and secondary metabolites in pharmaceutical sciences. Planta Med 2007; 73: 103-15.
13. Lull C, Wichers HJ, Savelkoul HF. Antiinflammatory and immunomodulating properties of fungal metabolites. Mediators Inflamm 2005; 2005: 63-80.
14. Donadio S, Monciardini P, Alduina R, et al. Microbial technologies for the discovery of novel bioactive metabolites. J Biotechnol 2002; 99: 187-98.
15. Behal V. Nontraditional microbial bioactive metabolites. Folia Microbiol (Praha) 2001; 46: 363-70.
16. Lock RL, Harry EJ. Cell-division inhibitors: new insights for future antibiotics. Nat Rev Drug Discov 2008; 7: 324-38.
17. Luzhetskyy A, Pelzer S, Bechthold A. The future of natural products as a source of new antibiotics. Curr Opin Investig Drugs 2007; 8: 608-13.
18. Alekshun MN. New advances in antibiotic development and discovery. Expert Opin Investig Drugs 2005; 14: 117-34.
19. Livermore DM. The need for new antibiotics. Clin Microbiol Infect 2004; 10 (Suppl 4): 1-9.
20. Cheng Q, Wang S, Salyers AA. New approaches for anti-infective drug discovery: antibiotics, vaccines and beyond. Curr Drug Targets Infect Disord 2003; 3: 66-75.
21. Ali ST, Gill AE, Lewendon A. Novel targets for antibiotic drug design. Curr Opin Investig Drugs 2002; 3: 1712-7.
22. Levy SB. The future of antibiotics: facing antibiotic resistance. Clin Microbiol Infect 2000; 6 (Suppl 3): 101-6.
23. Ozbay A, Karamperis N, Jorgensen KA. A review of the immunosuppressive activity of cyclosporine metabolites: new insights into an old issue. Curr Clin Pharmacol 2007; 2: 244-8.
24. Ting LS, Villeneuve E, Ensom MH. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit 2006; 28: 419-30.
25. Behnam SM, Behnam SE, Koo JY. Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use. J Drugs Dermatol 2005; 4: 189-94.
26. Oellerich M, Armstrong VW, Streit F, Weber L, Tonshoff B. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. Clin Biochem 2004; 37: 424-8.
27. Casanovas TT. Impact of cyclosporine on the development of immunosuppressive therapy in liver transplantation. Transplant Proc 2004; 36: 291S-294S.
28. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007; 58: 221-37.
29. Kreitman RJ. Immunotoxins for targeted cancer therapy. AAPS J 2006; 8: E532-E551.
30. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006; 6: 559-65.
31. Li Z, Yu T, Zhao P, Ma J. Immunotoxins and cancer therapy. Cell Mol Immunol 2005; 2: 106-12.
32. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 2005; 5: 543-9.
33. Fitzgerald DJ, Kreitman R, Wilson W, Squires D, Pastan I. Recombinant immunotoxins for treating cancer. Int J Med Microbiol 2004; 293: 577-82.
34. Kreitman RJ. Recombinant toxins for the treatment of cancer. Curr Opin Mol Ther 2003; 5: 44-51.
35. Payne G. Progress in immunoconjugate cancer therapeutics. Cancer Cell 2003; 3: 207-12.
36. Kim J, Park EJ. Cytotoxic anticancer candidates from natural resources. Curr Med Chem Anticancer Agents 2002; 2: 485-537.
37. Adams TH, Yu JH. Coordinate control of secondary metabolite production and asexual sporulation in Aspergillus nidulans. Curr Opin Microbiol 1998; 1: 674-7.
38. Pearce C. Biologically active fungal metabolites. Adv Appl Microbiol 1997; 44: 1-80.
39. Franco CM, Coutinho LE. Detection of novel secondary metabolites. Crit Rev Biotechnol 1991; 11: 193-276.
40. Multani PS, Grossbard ML. Monoclonal antibody-based therapies for hematologic malignancies. J Clin Oncol 1998; 16: 3691-710.
41. Siegall CB. Targeted toxins as anticancer agents. Cancer 1994; 74: 1006-12.
42. Hall WA. Immunotoxin treatment of brain tumors. Methods Mol Biol 2001; 166: 139-54.
43. Kreitman RJ, Pastan I. Immunotoxins in the treatment of hematologic malignancies. Curr Drug Targets 2006; 7: 1301-11.
44. Kreitman RJ. Recombinant immunotoxins for the treatment of haematological malignancies. Expert Opin Biol Ther 2004; 4: 1115-28.
45. Kreitman RJ, Pastan I. Immunobiological treatments of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003; 16: 117-33.
46. Kreitman RJ, Pastan I. Immunotoxins in the treatment of refractory hairy cell leukemia. Hematol Oncol Clin North Am 2006; 20: 1137-51.
47. Forero A, Lobuglio AF. History of antibody therapy for non-Hodgkin's lymphoma. Semin Oncol 2003; 30: 1-5.
48. Ross J, Gray K, Schenkein D, et al. Antibody-based therapeutics in oncology. Exp Rev Anticancer Ther 2003; 3: 107-21.
49. Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. Clin Cancer Res 2000; 6: 326-34.
50. Bull AT, Ward AC, Goodfellow M. Search and discovery strategies for biotechnology: the paradigm shift. Microbiol Mol Biol Rev 2000; 64: 573-606.
51. Serwe A, Anke T, Erkel G. The fungal secondary metabolite trichodimerol inhibits TGF-beta dependent cellular effects and tube formation of MDA-MB-231 cells. Invest New Drugs 2008.
52. Barnes-Seeman D, Corey EJ. A two-step total synthesis of the natural pentacycle trichodimerol, a novel inhibitor of TNF-alpha production. Org Lett 1999; 1: 1503-4.
53. Nicolaou KC, Simonsen KB, Vassilikogiannakis G, et al. Biomimetic Explorations Towards the Bisorbicillinoids: Total Synthesis of Bisorbicillinol, Bisorbibutenolide, and Trichodimerol. Angew Chem Int Ed Engl 1999; 38: 3555-9.
54. Mazzucco CE, Warr G. Trichodimerol (BMS-182123) inhibits lipopolysaccharide-induced eicosanoid secretion in THP-1 human monocytic cells. J Leukoc Biol 1996; 60: 271-7.
55. Lukasheva EV, Berezov TT. L-Lysine alpha-oxidase: physicochemical and biological properties. Biochemistry (Mosc) 2002; 67: 1152-8.
56. Kusakabe H, Kodama K, Kuninaka A, Yoshino H, Misono H, Soda K. A new antitumor enzyme, L-lysine alpha-oxidase from Trichoderma viride. Purification and enzymological properties. J Biol Chem 1980; 255: 976-81.
57. Osmani SA, Mirabito PM. The early impact of genetics on our understanding of cell cycle regulation in Aspergillus nidulans. Fungal Genet Biol 2004; 41: 401-10.
58. Oakley BR. Tubulins in Aspergillus nidulans. Fungal Genet Biol 2004; 41: 420-7.
59. Goldman GH, Kafer E. Aspergillus nidulans as a model system to characterize the DNA damage response in eukaryotes. Fungal Genet Biol 2004; 41: 428-42.
60. Oakley BR. Methods for isolating and analyzing mitotic mutants in Aspergillus nidulans. Methods Cell Biol 1999; 61: 347-68.
61. Lee HW, Cho CS, Kang SK, Yoo YS, Shin JS, Ahn SK. Design, synthesis, and antiangiogenic effects of a series of potent novel fumagillin analogues. Chem Pharm Bull (Tokyo) 2007; 55: 1024-9.
62. Lefkove B, Govindarajan B, Arbiser JL. Fumagillin: an antiinfective as a parent molecule for novel angiogenesis inhibitors. Exp Rev Anti Infect Ther 2007; 5: 573-9.
63. Furness MS, Robinson TP, Ehlers T, et al. Antiangiogenic agents: studies on fumagillin and curcumin analogs. Curr Pharm Des 2005; 11: 357-73.
64. Chu M, Mierzwa R, He L, et al. Structure of Sch 528647: a new antitumor antibiotic related to fumagillin. J Antibiot (Tokyo) 2001; 54: 1096-9.
65. Kawai K, Shiojiri H, Nakamaru T, et al. Cytotoxicity and genotoxicity of xenoclauxin and desacetyl duclauxin from Penicillium duclauxii (Delacroix). Cell Biol Toxicol 1985; 1: 1-10.
66. Kawai K, Nozawa Y, Ito T, Yamanaka N. Effects of xanthomegnin and duclauxin on culture cells of murine leukemia and Ehrlich ascitic tumor. Res Commun Chem Pathol Pharmacol 1982; 36: 429-38.
67. Buenz EJ, Bauer BA, Osmundson TW, Motley TJ. The traditional Chinese medicine Cordyceps sinensis and its effects on apoptotic homeostasis. J Ethnopharmacol 2005; 96: 19-29.
68. Zhu JS, Halpern GM, Jones K. The scientific rediscovery of a precious ancient Chinese herbal regimen: Cordyceps sinensis: part II. J Altern Complement Med 1998; 4: 429-57.
69. Boh B, Berovic M, Zhang J, Zhi-Bin L. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev 2007; 13: 265-301.
70. Yuen JW, Gohel MD. Anticancer effects of Ganoderma lucidum: a review of scientific evidence. Nutr Cancer 2005; 53: 11-17.
71. Lin ZB. Cellular and molecular mechanisms of immunomodulation by Ganoderma lucidum. J Pharmacol Sci 2005; 99: 144-53.
72. Sliva D. Cellular and physiological effects of Ganoderma lucidum (Reishi). Mini Rev Med Chem 2004; 4: 873-9.
73. Lin ZB, Zhang HN. Anti-tumor and immunoregulatory activities of Ganoderma lucidum and its possible mechanisms. Acta Pharmacol Sin 2004; 25: 1387-95.
74. Sliva D. Ganoderma lucidum (Reishi) in cancer treatment. Integr Cancer Ther 2003; 2: 358-64.
75. Shiao MS. Natural products of the medicinal fungus Ganoderma lucidum: occurrence, biological activities, and pharmacological functions. Chem Rec 2003; 3: 172-80.
76. Giannini G, Penco S, Pisano C, Riccioni T, Nasini G, Candiani G. Chrysanthones, a new source of fungal metabolites with potential antitumor and antiangiogenesis properties. Fitoterapia 2003; 74: 323-7.
77. Mujumdar AM. Cytochalasins: a short review. Hindustan Antibiot Bull 1989; 31: 15-24.
78. Natori S. Cytochalasins-actin filament modifiers as a group of mycotoxins. Dev Toxicol Environ Sci 1986; 12: 291-9.
79. Henney CS. The use of cytochalasins to probe the immunobiolgoy of lymphocytes. Front Biol 1978; 46: 191-215.
80. Tamm C. Chemistry and biosynthesis of cytochalasins. Front Biol 1978; 46: 15-51.
81. Weihing RR. In vitro interactions of cytochalasins with contractile proteins. Front Biol 1978; 46: 431-44.
82. Guimaraes LM, Furlan RL, Garrido LM, Ventura A, Padilla G, Facciotti MC. Effect of pH on the production of the antitumor antibiotic retamycin by Streptomyces olindensis. Biotechnol Appl Biochem 2004; 40: 107-11.
83. Giudici R, Pamboukian CR, Facciotti MC. Morphologically structured model for antitumoral retamycin production during batch and fed-batch cultivations of Streptomyces olindensis. Biotechnol Bioeng 2004; 86: 414-24.
84. Pamboukian CR, Facciotti MC. Production of antitumoral retamycin during fed-batch fermentations of Streptomyces olindensis. Appl Biochem Biotechnol 2004; 112: 111-22.
85. Stirpe F. Ribosome-inactivating proteins. Toxicon 2004; 44: 371-83.
86. Correll CC, Yang X, Gerczei T, Beneken J, Plantinga MJ. RNA recognition and base flipping by the toxin sarcin. J Synchrotron Radiat 2004; 11: 93-6.
87. Donachie SP, Hou S, Lee KS, et al. The Hawaiian Archipelago: a microbial diversity hotspot. Microb Ecol 2004; 48: 509-20.
88. Ahmed HY, Eissa SA, Ghoneimy EA, Ragab AM, Sherif MM, El Shikh ME. Characterization of [4-(hex-1-Yen-3-ene),4(pent-1,3-diene)]-amine; A Novel Hepatoma Growth-Inhibition Factor from Trichoderma viride. Sc J Az Med Fac (Girls) 2008; 29: 1-17.
89. Phuwapraisirisan P, Rangsan J, Siripong P, Tip-Pyang S. 9-epi-Viridiol, a novel cytotoxic furanosteroid from soil fungus Trichoderma virens. Nat Prod Res 2006; 20: 1321-5.
90. Sun Y, Tian L, Huang YF, Sha Y, Pei YH. A new cyclotetrapeptide from marine fungus Trichoderma reesei. Pharmazie 2006; 61: 809-10.
91. Landis-Piwowar KR, Chen D, Cui QC, et al. Apoptotic-inducing activity of novel polycyclic aromatic compounds in human leukemic cells. Int J Mol Med 2006; 17: 931-5.
92. Veselkov AN, Maleev VY, Glibin EN, Karawajew L, Davies DB. Structure-activity relation for synthetic phenoxazone drugs: evidence for a direct correlation between DNA and pro-apoptotic activity. Eur J Biochem 2003; 270: 4200-7.
93. Rether J, Serwe A, Anke T, Erkel G. Inhibition of inducible tumor necrosis factor-alpha expression by the fungal epipolythiodiketopiperazine gliovirin. Biol Chem 2007; 388: 627-37.